JPMorgan Chase & Co. Purchases New Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

JPMorgan Chase & Co. bought a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 728,919 shares of the company's stock, valued at approximately $5,336,000. JPMorgan Chase & Co. owned approximately 1.15% of ABIVAX Société Anonyme as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of ABVX. GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $29,000. R Squared Ltd acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at approximately $36,000. Finally, abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme by 34.1% in the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock valued at $3,105,000 after buying an additional 107,750 shares during the last quarter. 47.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ABVX has been the topic of a number of research reports. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Morgan Stanley restated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $38.00.

ABIVAX Société Anonyme Trading Up 7.8 %

Shares of ABVX traded up $0.51 during trading hours on Wednesday, hitting $7.01. 109,233 shares of the stock were exchanged, compared to its average volume of 130,463. The business has a 50-day moving average of $6.68 and a 200-day moving average of $7.66. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $16.63.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.